Revenue Breakdown
Composition ()
No data
Revenue Streams
Lisata Therapeutics Inc (LSTA) generates its revenue primarily from PCT Segment, which accounts for 100.0% of total sales, equivalent to $7.92M. Understanding this concentration is critical for investors evaluating how LSTA navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Lisata Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -21614.29%, while the net margin is -19474.29%. These profitability ratios, combined with a Return on Equity (ROE) of -71.45%, provide a clear picture of how effectively LSTA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, LSTA competes directly with industry leaders such as CING and RNTX. With a market capitalization of $40.22M, it holds a significant position in the sector. When comparing efficiency, LSTA's gross margin of 100.00% stands against CING's N/A and RNTX's N/A. Such benchmarking helps identify whether Lisata Therapeutics Inc is trading at a premium or discount relative to its financial performance.
